All In Biotech

Drug Trial Radar · NCT04683328

The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care

An Adaptive, Randomized, Double-blinded, Placebo-controlled, Phase II/III Trial of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in Patients With Severe COVID-19 Admitted to High Dependence or Intensive Care Unit (MASP3 Trial)

Last checked: Nov 19, 2026Latest source record: Jan 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 560 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

560

Planned (sponsor's estimate)

Start

Feb 25, 2021

Primary completion

May 25, 2021

Study completion Nov 25, 2021

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Dec 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an adaptive, randomized, double-blinded, placebo-controlled, Phase II/III study conducted to evaluate the effect of SCTA01 on participant survival and clinical efficacy in participants with severe COVID-19 admitted to high dependence or ICUs. The study duration of subject participation will be up to: 120 days Participants will receive a single intravenous (IV) infusion of SCTA01 at Treatment day 1. Follow up visits will be up to 120 days or early withdrawal visit.

Conditions

  • Covid19

Interventions

  • SCTA01Biological

    Recombinant anti-SARS-CoV-2 spike protein monoclonal antibody

  • SCTA01 PlaceboBiological

    The excipients of SCTA01

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortality rate at D29Time frame: Day 29

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.